To investigate the associations of MRI radiological features and prognosis of glioma with the status of isocitrate dehydrogenase 1 (IDH1). A total of 116 patients with gliomas were retrospectively recruited from January 2013 to December 2015. All patients were undergone routine MRI (T1WI, T2WI, T2-FLAIR) scanning and contrast-enhanced MRI T1WI before surgery. The following imaging features were included: tumor location, diameter, the pattern of growth, boundary, the degree of enhancement, mass effect, edema, cross the middle line, under the ependyma. χ and Fisher's exact probability tests were used to determine the significance of associations between MRI features and IDH1 mutation of glioma. The survival distributions were estimated using Kaplan-Meier compared by Log-rank test. Univariate and multivariate analyses were performed using Cox regression. Gliomas with IDH1 mutant were significantly more likely to exhibit homogeneous signal intensity ( = 0.009) on non-contrast MRI protocols and less contrast enhancement ( = 0.000) on contrast enhanced T1WI. IDH1 mutant type glioma was more inclined to cross the midline to invade contralateral hemisphere ( = 0.001). The overall survival between IDH1 mutated and wild type glioma were significantly different ( = 0.000), age ≤ 40 ( = 0.003), KPS scores > 80 before operation ( = 0.000) and low grade glioma ( = 0.000). Our results suggest IDH1 mutant in gliomas is more likely to exhibit homogeneous signal intensity, less contrast enhancement and more inclined to cross the midline. Patients with IDH1 mutated, age ≤ 40, KPS scores > 80 before operation and low-grade glioma may have a longer life and better prognosis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280555 | PMC |
http://dx.doi.org/10.3389/fonc.2020.00852 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!